Randomised study to compare aspirin versus hydroxyurea/aspirin in 'intermediate risk' primary thrombocythaemia (PT) and hydroxyurea/aspirin versus anagrelide/aspirin in 'high risk' primary thrombocythaemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72251782

Enrollment

1600

Registered

2000-10-25

Start date

1997-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukaemia Cancer Leukaemia

Interventions

'Low risk': aspirin only 'Intermediate risk': aspirin/aspirin plus hydroxyurea 'High risk': aspirin plus hydroxyurea/aspirin plus anagrelide

Eligibility

Inclusion criteria

Inclusion criteria: All patients over 18 years of age meeting diagnostic criteria of PT

Exclusion criteria

Exclusion criteria: Severe heart disease excludes patients from the 'high risk' study.

Design outcomes

Primary

Measure	Time frame
Vascular occlusion, haemorrhagic events, death, drug side-effects, transformation to acute leukaemia or myelofibrosis	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026